


22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin

Cat. No.:	HY-146756
CAS No.:	2780409-77-8
Molecular Formula:	C ₃₀ H ₄₂ N ₂ O ₆
Molecular Weight:	526.66
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin (compound 6n) is an antibacterial pleuromutilin derivative against Gram-positive pathogens (GPPs) and <i>Mycoplasma pneumoniae</i> ^[1] .								
In Vitro	<p>22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin (compound 6n) (0.0625 -128 µg/mL, 8 h) shows antibacterial activity with MICs of 0.0625, 0.5, 8, 0.125, 0.0625, and 0.5 µg/mL against MSSA, MRSA, <i>E.faecium</i>, <i>M.pneumonia</i> (ATCC15331), <i>M.pneumonia</i> (ATCC29342), and <i>M.pneumonia</i> (resistant strain, clinically isolated strain), respectively^[1].</p> <p>22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin (0-10 µg/mL, 72 h) shows low cytotoxicity in human cancer cells^[1].</p> <p>22-((4-Methoxyphenyl)urea-1-yl)-22-deoxypleuromutilin exhibits good ADMET properties with high LogS, attractive ALogP, low PPB, non-Ames toxic, and non-carcinogenic^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Five human cancer cell lines (HeG2, U87, HGC27, HT29 and MCF2)</td> </tr> <tr> <td>Concentration:</td> <td>0-10 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Showed low cytotoxicity ((IC₅₀>10 µmol/L).</td> </tr> </table>	Cell Line:	Five human cancer cell lines (HeG2, U87, HGC27, HT29 and MCF2)	Concentration:	0-10 µg/mL	Incubation Time:	72 h	Result:	Showed low cytotoxicity ((IC ₅₀ >10 µmol/L).
Cell Line:	Five human cancer cell lines (HeG2, U87, HGC27, HT29 and MCF2)								
Concentration:	0-10 µg/mL								
Incubation Time:	72 h								
Result:	Showed low cytotoxicity ((IC ₅₀ >10 µmol/L).								

REFERENCES

[1]. Guangxu Wu, et al. Design, synthesis and antibacterial evaluation of pleuromutilin derivatives. *Bioorg Med Chem.* 2022 Apr 1;59:116676.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA